Cardio Diagnostics has signed an agreement with AI-driven business Aimil and healthcare test provider Dr Lal PathLabs to introduce the PrecisionCHD coronary heart disease (CHD) test in India.
The agreement marks Cardio Diagnostics’ first expansion outside the US and aims to address the growing challenge of cardiovascular disease in India, where the prevalence of CHD ranges from up to 7.4% in rural areas to 13% in urban populations.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company’s clinical blood test combines epigenetic and genetic science with AI to detect CHD at the molecular level. The test provides physicians with insights into the molecular mechanisms behind the disease, supporting ongoing management and personalised treatment.
Unlike traditional angiograms, PrecisionCHD can also detect non-obstructive CHD, including myocardial infarction with no obstructive coronary arteries (MINOCA) and ischemia with no obstructive coronary arteries (INOCA).
Data supporting PrecisionCHD’s ability to detect INOCA and MINOCA were recently presented at the American Heart Association Scientific Sessions held in New Orleans, US.
The initial phase of this collaboration involves integrating the test within Dr Lal PathLabs’ network of more than 290 clinical laboratories and over 300 MD pathologists, ensuring compliance with Indian regulatory and clinical protocols.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOnce integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.
Cardio Diagnostics CEO and co-founder Dr Meesha Dogan said: “This partnership is a major step forward in democratising access to advanced cardiovascular diagnostics and is a result of our ongoing effort to expand the reach of our technology beyond the US market.”
Dr Lal PathLabs CEO Shankha Banerjee said: “By integrating molecular-level detection of coronary heart disease into our services, we can help cardiologists and physicians identify disease earlier and support more effective, personalised treatment strategies.”
The collaboration aims to expand access to precision medicine and support early detection and improved management of heart disease in India.
